Dyne Therapeutics Inc (NASDAQ: DYN) on Friday, plunged -31.15% from the previous trading day, before settling in for the closing price of $23.05. Within the past 52 weeks, DYN’s price has moved between $15.22 and $47.45.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 12.26%. With a float of $77.75 million, this company’s outstanding shares have now reached $101.75 million.
Let’s determine the extent of company efficiency that accounts for 141 employees. In terms of profitability, gross margin is 64.28%, operating margin of -8301.64%, and the pretax margin is -7774.92%.
Dyne Therapeutics Inc (DYN) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Dyne Therapeutics Inc is 23.60%, while institutional ownership is 86.89%. The most recent insider transaction that took place on Dec 11 ’24, was worth 65,632. In this transaction Chief Scientific Officer of this company sold 2,334 shares at a rate of $28.12, taking the stock ownership to the 201,685 shares. Before that another transaction happened on Dec 11 ’24, when Company’s SVP, Head of Finance & Admin. sold 1,455 for $28.12, making the entire transaction worth $40,915. This insider now owns 127,078 shares in total.
Dyne Therapeutics Inc (DYN) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 12.26% per share during the next fiscal year.
Dyne Therapeutics Inc (NASDAQ: DYN) Trading Performance Indicators
Dyne Therapeutics Inc (DYN) is currently performing well based on its current performance indicators. A quick ratio of 17.02 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.56, a number that is poised to hit -0.94 in the next quarter and is forecasted to reach -3.77 in one year’s time.
Technical Analysis of Dyne Therapeutics Inc (DYN)
Looking closely at Dyne Therapeutics Inc (NASDAQ: DYN), its last 5-days average volume was 2.75 million, which is a jump from its year-to-date volume of 2.48 million. As of the previous 9 days, the stock’s Stochastic %D was 14.34%. Additionally, its Average True Range was 1.97.
During the past 100 days, Dyne Therapeutics Inc’s (DYN) raw stochastic average was set at 3.30%, which indicates a significant decrease from 9.43% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 155.38% in the past 14 days, which was higher than the 99.63% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $27.34, while its 200-day Moving Average is $32.46. However, in the short run, Dyne Therapeutics Inc’s stock first resistance to watch stands at $18.98. Second resistance stands at $22.10. The third major resistance level sits at $24.19. If the price goes on to break the first support level at $13.77, it is likely to go to the next support level at $11.68. Now, if the price goes above the second support level, the third support stands at $8.57.
Dyne Therapeutics Inc (NASDAQ: DYN) Key Stats
Market capitalization of the company is 1.62 billion based on 101,766K outstanding shares. Right now, sales total 0 K and income totals -235,940 K. The company made 0 K in profit during its latest quarter, and -97,130 K in sales during its previous quarter.
